KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesR&D In ProcessReceivables - NetReceivables - OtherShares Repurchased
Ratios

Eli Lilly (LLY) Accumulated Depreciation & Amortization (2016 - 2025)

Eli Lilly (LLY) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 13.02% year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Dec 2025, up 13.02%, and an annual FY2025 reading of $2.0 billion, up 13.02% over the prior year.
  • Accumulated Depreciation & Amortization was $2.0 billion for Q4 2025 at Eli Lilly, up from $1.4 billion in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.0 billion in Q4 2025 and bottomed at $350.3 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization increased 28.03% in 2021, then decreased 16.85% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.5 billion in 2021, then fell by 1.62% to $1.5 billion in 2022, then increased by 0.3% to $1.5 billion in 2023, then rose by 15.72% to $1.8 billion in 2024, then increased by 13.02% to $2.0 billion in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for LLY at $2.0 billion in Q4 2025, $1.4 billion in Q3 2025, and $941.3 million in Q2 2025.